The efficacy and QOL in a cancer pain patient who converted to transdermal fentanyl from low-dose morphine (n=5) or high-dose morphine (n=5) were retrospectively compared. Cancer pain control was evaluated by visual analogue scales (VAS) score. Patients switched from low-dose morphine demonstrated significantly better scales. The number of morphine rescues was also significantly less in the low-dose conversion group. In conclusion, conversion from low-dose morphine is useful for cancer pain control from the aspect of efficacy and QOL.

Download full-text PDF

Source

Publication Analysis

Top Keywords

low-dose morphine
16
cancer pain
16
conversion low-dose
8
transdermal fentanyl
8
efficacy qol
8
morphine n=5
8
pain control
8
morphine
6
low-dose
5
[direct conversion
4

Similar Publications

Corticosteroid signaling plays a critical role in modulating the neural systems underlying reward and addiction, but the specific contributions of glucocorticoid receptors (GRs) and mineralocorticoid receptors (MRs) in the medial prefrontal cortex (mPFC) to opioid reward and dopaminergic plasticity remain unclear. Here, we investigated the effects of intra-mPFC injection of corticosteroid receptor ligand (corticosterone; CORT), glucocorticoid receptor antagonist (RU38486; RU), and mineralocorticoid receptor antagonist (spironolactone; SP) on morphine-induced conditioned place preference (CPP) and dopamine transporter (DAT) expression in the mPFC. Adult male Wistar rats received intra-mPFC injections of CORT, RU, SP, or their respective vehicles prior to morphine CPP conditioning.

View Article and Find Full Text PDF

Background: Morphine analgesic tolerance (MAT) limits the clinical application of morphine in the management of chronic pain. IIK7 is a melatonin type 2 (MT2) receptor agonist known to have antioxidant properties. Oxidative stress is recognized as a critical factor in MAT.

View Article and Find Full Text PDF

While low-dose cannabinoid 2 (CB2) receptor agonists attenuate morphine tolerance in cancer pain models, chemokine ligand 12 (CXCL12)/chemokine receptor 4 (CXCR4) expression induces morphine tolerance. Whether CB2 receptor agonists attenuate morphine tolerance by modulating CXCL12/CXCR4 signaling or whether CXCL12/CXCR4 signaling affects the mu opioid receptor (MOR) in the development of morphine tolerance in cancer pain remains unclear. In this study, we investigated the attenuation of morphine tolerance by a non-analgesic dose of the CB2 receptor agonist AM1241, focusing specifically on the modulation of CXCL12/CXCR4 signaling and its effect on the MOR.

View Article and Find Full Text PDF

The Effects of Low-Dose Morphine on Sleep and Breathlessness in COPD: A Randomized Trial.

Chest

December 2024

Flinders Health and Medical Research Institute/Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia.

Background: Low-dose morphine may be prescribed to reduce chronic breathlessness in COPD. Subjective findings suggest morphine may influence breathlessness through sleep-related mechanisms. However, concerns exist regarding opioid safety in COPD.

View Article and Find Full Text PDF

The dual modulating effects of neuropeptide FF on morphine-induced analgesia at the spinal level.

Neuroscience

January 2025

Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China. Electronic address:

Increasing evidence indicates that neuropeptide FF (NPFF) produces analgesic effects and augments opioid-induced analgesia at the spinal level. However, our recent research demonstrated that NPFF exerted complex opioid-modulating effects in an inflammatory pain model after intrathecal (i.t.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!